Gene Expression analysis of hESC B2M knock-out

ABSTRACT: The clinical use of human pluripotent stem cells and their derivatives is limited by the rejection of transplanted cells due to differences in their HLA genes. This has led to the proposed use of histocompatible, patient-specific stem cells, however the preparation of many different stem cell lines for clinical use is a daunting task. Here we develop two distinct genetic engineering approaches that address this problem. First, we use a combination of gene targeting and mitotic recombination to derive HLA-homozygous embryonic stem cell (ESC) subclones from an HLA-heterozygous parental line. A small bank of HLA-homozygous stem cells with common haplotypes would match a significant proportion of the population. Second, we derive HLA class I-negative cells by targeted disruption of both al

ORGANISM(S): Homo sapiens

SUBMITTER: Laura Riolobos 

PROVIDER: E-GEOD-42289 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress